| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 09/06/2006 | CN1827648A Phi C31 integrase polyclonal antibody and its use |
| 09/06/2006 | CN1827647A Recombinant monoclonal antibody against EGFR |
| 09/06/2006 | CN1827646A Chemokine receptors 88-2b[ckr-3] and 88c and their antibodies |
| 09/06/2006 | CN1827645A Lomefloxacin conjugate and its preparing method and use |
| 09/06/2006 | CN1827644A Pefloxacin couple and its preparing method and use |
| 09/06/2006 | CN1827643A Danofloxacin couple and its preparing method and use |
| 09/06/2006 | CN1827642A Ofloxacin couple and its preparing method and use |
| 09/06/2006 | CN1827639A 新的细胞因子zalpha11配体 New cytokine zalpha11 Ligand |
| 09/06/2006 | CN1827168A Treatment of t cell mediated autoimmune disorders |
| 09/06/2006 | CN1273601C Expression carrier for high-efficient screening target protein, its preparation method and use |
| 09/06/2006 | CN1273593C Gene cloning of polyepitope antigen of hepatitis C virus and its coding sequence |
| 09/06/2006 | CN1273489C Monoclone antibody against HnRNP A2/B1 antigen, its preparation and use |
| 09/06/2006 | CN1273488C Gene reform immune globulin with low immunogenicity and its application |
| 09/06/2006 | CN1273485C Immunoglobulin sample receptor originated from human dendritic cell, its coding sequence and application |
| 09/06/2006 | CN1273192C Method and composition for altering a T cell mediated pathology |
| 09/06/2006 | CN1273191C Method and composition for altering a B cell mediated pathology |
| 09/05/2006 | US7101990 Bax-responsive genes for drug target identification in yeast and fungi |
| 09/05/2006 | US7101984 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 09/05/2006 | US7101980 Derivatives, conjugates, and antibodies for detecting ecstasy-class analytes |
| 09/05/2006 | US7101979 Antibodies to antiangiogenic compositions and methods |
| 09/05/2006 | US7101978 TNF-α binding molecules |
| 09/05/2006 | US7101977 Targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor |
| 09/05/2006 | US7101976 Targeting the extracellular domain of EphA2 and operating to redirect the function of EphA2 to selectively block the growth and invasiveness of metastatic cells |
| 09/05/2006 | US7101975 Method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and β1 integrins |
| 09/05/2006 | US7101973 β-amyloid peptide-binding proteins and polynucleotides encoding the same |
| 09/05/2006 | US7101965 Peptides of IL-2 |
| 09/05/2006 | US7101962 Antibodies of the P2Y10 receptor useful in altering T lymphocyte function |
| 09/05/2006 | US7101851 IgE receptor antagonists |
| 09/05/2006 | US7101850 WISP polypeptides and nucleic acids encoding same |
| 09/05/2006 | US7101849 ωconotoxin peptides |
| 09/05/2006 | US7101840 Polymeric drug formulations |
| 09/05/2006 | US7101787 System and method for minimizing increases in via resistance by applying a nitrogen plasma after a titanium liner deposition |
| 09/05/2006 | US7101714 Nucleotide sequences coding polypeptide for us e in the diagnosis, prevention and treatment of inflammatory defects |
| 09/05/2006 | US7101699 Comprises enzymatic polypeptide for treatment and prevention of neurodegenerative and cell proliferative disorders; wound healing agents |
| 09/05/2006 | US7101689 Interleukin-18 binding proteins, their preparation and use |
| 09/05/2006 | US7101688 Method of producing heteromultimeric mammalian proteins in plants |
| 09/05/2006 | US7101680 Method for detecting the presence of monomeric brain associated human glutamine synthetase |
| 09/05/2006 | US7101679 Marker for neuromyelitis optica |
| 09/05/2006 | US7101678 Method for detecting or quantifying basophils and eosinophils |
| 09/05/2006 | US7101675 Modulators of regulatory proteins |
| 09/05/2006 | US7101674 Antiidiotypic antibody for treating prevention and diagnosis of sepsis, inflammation, cancer and autoimmune disorders |
| 09/05/2006 | US7101662 Generating nonradioactive marker for use in genetic analysis; obtain adjusted adaptor nucleotide sequences, incubate with target sequences, translated and recover protein |
| 09/05/2006 | US7101559 Immunomodulatory protein and useful embodiments thereof |
| 09/05/2006 | US7101555 Microorganismal polypeptides for use in diagnosis and treatment of respiratory system disorders; genetic vaccines |
| 09/05/2006 | US7101554 Picornaviruses, vaccines and diagnostic kits |
| 09/05/2006 | US7101552 Preferential particle for inducing immume respone to viral disease and lymphadenopathy associated viruses |
| 09/05/2006 | US7101551 Substance which inhibits binding between E2/NS1 protein of hepatitis C virus and cell infectious with hepatitis C virus, a cell expressing CD81, or CD81 |
| 09/05/2006 | US7101550 Agents for modulating PD-1, B7-4, and the interaction between B7-4 and PD-1 in order to modulate a costimulatory or an inhibitory signal in a immune cell resulting in modulation of the immune response |
| 09/05/2006 | US7101549 nucleic acid molecules and polypeptide molecules that encode glycoprotein VI; modulating agents in regulating a variety of cellular processes |
| 09/05/2006 | US7101548 Functional role of adrenomedullin (AM) and the gene-related product (PAMP) in human pathology and physiology |
| 09/05/2006 | CA2178504C Immunoassays for prostate specific antigen |
| 09/05/2006 | CA2143642C Immunoreactive peptides from epstein-barr virus |
| 08/31/2006 | WO2006091871A1 Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| 08/31/2006 | WO2006091824A2 Peptides for detection of antibody to porcine reproductive respiratory syndrome virus |
| 08/31/2006 | WO2006091796A2 Compositions and methods for diagnosing and treating retinal diseases |
| 08/31/2006 | WO2006091381A1 Humanized anti-ghrelin antibodies |
| 08/31/2006 | WO2006091326A1 Anti-prl-3 antibodies and methods of use thereof |
| 08/31/2006 | WO2006090932A1 Surrogate marker for sulfonamide compound |
| 08/31/2006 | WO2006090750A1 ANTI-IgSF4 ANTIBODY AND UTILIZATION OF THE SAME |
| 08/31/2006 | WO2006090679A1 METHOD FOR DETECTION OF DNA DAMAGE USING Frag1 GENE OR GENE PRODUCT THEREOF AS MARKER |
| 08/31/2006 | WO2006090241A2 Method of creating or selecting recombinant genes |
| 08/31/2006 | WO2006090096A1 Composition, kit and method for fixing cells |
| 08/31/2006 | WO2006089980A1 Nucleic acids and allergens of olive tree pollen of defined olive tree varieties and applications thereof |
| 08/31/2006 | WO2006089549A1 Ykl-40 monoclonal antibodies |
| 08/31/2006 | WO2006089422A1 Protein and its use in diagnosing alzheimer's disease |
| 08/31/2006 | WO2006074914A3 Human rna helicase and therapeutic uses thereof |
| 08/31/2006 | WO2006073941A3 Polypeptides that bind br3 and uses thereof |
| 08/31/2006 | WO2006071206A3 Immunoglobulins whith potent and broad antiviral activity |
| 08/31/2006 | WO2006070286A3 Monoclonal antibodies against nkg2a |
| 08/31/2006 | WO2006066568A3 Antibody |
| 08/31/2006 | WO2006065975A3 Methods of treating ankylosing spondylitis using anti-tnf antibodies and peptides of human tumor necrosis factor |
| 08/31/2006 | WO2006064121A3 Cytotoxic antibody directed against type b lymphoid hematopoietic proliferations |
| 08/31/2006 | WO2006028956A3 Anti-fc-gamma riib receptor antibody and uses therefor |
| 08/31/2006 | WO2006023403A3 Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity |
| 08/31/2006 | WO2006002064A3 Antibody inhibiting stem cell factor activity and use for treatment of asthma |
| 08/31/2006 | WO2005047307A3 Il-18 binding proteins |
| 08/31/2006 | WO2005018554A3 Isolated heat-inducible cell surface protein and hyperthermia-based tumor immunotargeting therapy |
| 08/31/2006 | WO2005016281A3 Diagnosis and treatment of malignant neoplasms |
| 08/31/2006 | WO2004033648A3 Isolated mammalian membrane protein genes; related reagents |
| 08/31/2006 | US20060195946 For biosynthesis of human growth hormone; monoclonal antibodies with effector function; signal sequences |
| 08/31/2006 | US20060194957 Comprising human immunoglobulin g1 fc region; mediates antibody-dependent cell-mediated cytotoxicity in presence of effector cells more effectively; binds fc gamma receptor iii with better affinity |
| 08/31/2006 | US20060194956 Method for generating antibodies |
| 08/31/2006 | US20060194955 separating antibodies from proteases; provide a mutated immunoglobulin-binding protein ligand that exhibits an improved stability at increased pH-values, and accordingly an improved tolerance to cleaning under alkaline conditions |
| 08/31/2006 | US20060194954 Immunoadhesin protein for use as tools in targeting preferential cells for destruction |
| 08/31/2006 | US20060194953 Antibody purification by protein a and ion exchange chromatography |
| 08/31/2006 | US20060194952 Enhancing the circulating half-life of antibody-based fusion proteins |
| 08/31/2006 | US20060194950 separating antibodies from proteases; provide a mutated immunoglobulin-binding protein ligand that exhibits an improved stability at increased pH-values, and accordingly an improved tolerance to cleaning under alkaline conditions |
| 08/31/2006 | US20060194751 Streptococcus pyogenes antigens |
| 08/31/2006 | US20060194731 Using tumor antigens to elicit immune response targeted to cancer cells; immunotherapy |
| 08/31/2006 | US20060194340 Also, utilization of mass spectrometry (e.g., Surface Enhanced Laser Desorption Ionization, Maldi Qq TOF, MS/MS, TOF TOF, ESI-Q-TOF or ION-TRAP) to elucidate particular indicative or predictive biopolymer markers |
| 08/31/2006 | US20060194339 Isolated biopolymer marker peptide; using mass spectrometry to determine markers predictive of insulin resistance |
| 08/31/2006 | US20060194338 Characterizing the existence of a disease state; particularly to the utilization of mass spectrometry to elucidate particular biopolymer markers indicative or predictive of a particular disease state |
| 08/31/2006 | US20060194337 Characterizing the existence of a disease state; particularly to the utilization of mass spectrometry to elucidate particular biopolymer markers indicative or predictive of a particular disease state |
| 08/31/2006 | US20060194318 Cultured cd14+ antigen presenting cells |
| 08/31/2006 | US20060194315 Compositions and methods for the control, differentiaton and/or manipulation of pluripotent cells through a gamma-secretase signaling pathway |
| 08/31/2006 | US20060194293 Rb1 gene induced protein (rb1cc1) and gene |
| 08/31/2006 | US20060194291 Comprising human immunoglobulin g1 fc region, which mediates antibody-dependent cell-mediated cytotoxicity in presence of effector cells more effectively; binds fc gamma receptor iii with better affinity |
| 08/31/2006 | US20060194290 Polypeptide variants with altered effector function |
| 08/31/2006 | US20060194286 Apo-2LI and Apo-3 polypeptides |
| 08/31/2006 | US20060194283 Secreted and transmembrane polypeptides and nucleic acids encoding the same |